Orchid Chemicals & Pharmaceuticals Ltd
Unaudited Financial Results for nine months ended December 31, 2003
           
(Rs.Lakhs)
Sl No Particulars
Three months ended
December 31, 2003
(Unaudited)
Three months ended
December 31, 2002
(Unaudited)
Nine months ended
December 31, 2003
(Unaudited)
Nine months ended
December 31, 2002
(Unaudited)
Year ended March 31, 2003
(Audited)
1
 Sales and Operating Income
17090.41
12828.42
50565.8
34645.18
54141.43
2
 Other Income
39.13
8.68
103.71
39.54
111.38
3
 Total Expenditure
13447.22
10278.29
39768.85
27670.32
43289.70
a) Decrease/(Increase) in Stock in trade
(424.56)
1034.65
(3586.38)
(2424.91)
(4702.99)
b) Consumption of raw materials
8393.34
5884.26
28265.87
19563.8
31910.92
c) Staff Cost
1193.74
711.17
3362.97
2171.77
3403.16
d) Other Expenditure
4284.70
2648.21
11726.39
8359.66
12678.61
4
Profit before Interest, Depreciation & Tax (1+2-3)
3682.32
2558.81
10900.66
7014.40
10963.11
5
 Interest and Finance Charges
1642.09
1015.19
4411.66
2804.8
4207.69
6
 Depreciation
1288.21
987.37
4018.42
2878.11
4030.71
7
 Profit before tax (4-5-6)
752.02
556.25
2470.58
1331.49
2724.71
8
 Provision for Taxation
      Current Tax
43.04
-
143.10
-
      Deferred Tax
(131.60)
184.50
379.83
770.65
9
 Net Profit (7-8)
840.58
371.75
2327.48
951.66
1954.06
10
 Paid- up Equity Share Capital (Face value of Rs. 10 each)
3238.19
3238.19
3238.19
3238.19
3238.19
11
 Reserves excluding Revaluation Reserves
-
-
36990.13
12
 Basic & Diluted Earnings per Share (Rs.)
2.60**
1.24**
7.19**
3.31**
6.61
** EPS is for the period (not annualised) after providing for taxes
   
 
SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED
         
(Rs.Lakhs)
Particulars
Three months ended
December 31, 2003
Three months ended
December 31, 2002
Nine months ended
December 31, 2003
Nine months ended
December 31, 2002
Year ended March 31, 2003
1. Segment Revenue        
a. Bulk
14984.62
11890.2
44198.71
31894.25
50066.25
b. Formulations
2331.12
1515.59
7915.93
4154.35
6346.07
Total
17315.74
13405.79
52114.64
36048.60
56412.32
Less: Inter segment revenue
225.33
577.37
1548.84
1403.42
2270.89
Net Sales / Income from Operations
17090.41
12828.42
50565.80
34645.18
54141.43
 
 
2. Segment Results: (Profit/(Loss) before interest & tax)
a. Bulk
2512.53
1472.64
6724.5
3841.72
7315.15
b. Formulations
49.87
90.12
261.45
255.03
(452.40)
Total
2562.40
1562.76
6985.95
4096.75
6862.75
 
Less: i) Interest (Net)
1642.09
1015.19
4411.66
2804.80
4207.69
ii) Other unallocable expenditure net of unallocable income
168.29
(8.68)
103.71
(39.54)
(69.65)
Total Profit Before Tax
752.02
556.25
2470.58
1331.49
2724.71
 
3. Capital Employed
a. Bulk
120560.36
74785.03
120560.36
74785.03
98935.81
b. Formulations
9611.45
4423.9
9611.45
4423.9
9350.00
Total
130171.81
79208.93
130171.81
79208.93
108285.81
 
  • The Company received 14 complaints during the quarter ended December 31, 2003 from the shareholders, all the complaints have been resolved and no complaints were pending as on December 31,2003.
  • Previous period figures have been regrouped wherever necessary.
  • During the quarter, the Company received approval from the US FDA for its sterile lyophilized product, Cefazolin
    produced at its Alathur facility.
  • The statutory auditors carried out limited review of the financial results and the results were taken on
    record by the Board of Directors at its meeting held on Thursday, January 15, 2004

Place : Chennai
Date : 15-January-2004

For and on behalf of the Board

K.Raghavendra Rao
Managing Director